Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04218851 · ClinicalTrials.gov registry record · Phase 2
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04218851 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 31 participants.
The verdict
NCT04218851, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to \<18 years of age with invasive aspergillosis (IA).
Interventions
- DRUG Posaconazole IV
- DRUG Posaconazole PFS
- DRUG Posaconazole tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-07-02 |
| Est. Completion | 2023-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04218851
The ClinicalTrials.gov registry entry for NCT04218851 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Posaconazole IV is the first listed.
NCT04218851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04218851 about?
NCT04218851 is a clinical study titled "Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)". This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to \<18 years of age with invasive aspergillosis (IA).
What is the current status of trial NCT04218851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-07-02. Estimated completion is 2023-12-18.
What interventions are being tested in trial NCT04218851?
The interventions under investigation include: Posaconazole IV (DRUG), Posaconazole PFS (DRUG), Posaconazole tablet (DRUG).
Who is sponsoring clinical trial NCT04218851?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.